CUTIA THERAPEUTICS |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.86 HKD | +3.16% |
|
+9.24% | -37.52% |
| 03:57am | Cutia Therapeutics Plans Up to 50 Million Yuan Share Repurchase | MT |
| Jul. 02 | Cutia Therapeutics Enrolls Final Patient in Phase II Trial of Weight Loss Drug | MT |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 3,034 | 1,884 | - | - |
| Enterprise Value (EV) 1 | 2,475 | 2,107 | 2,109 | 2,311 |
| P/E ratio | -1.04 x | -3.98 x | -4.98 x | -10.1 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | 22 x | 6.84 x | 3.64 x | 2.16 x |
| EV / Revenue | 18 x | 7.65 x | 4.07 x | 2.64 x |
| EV / EBITDA | -4.97 x | -4.75 x | -6.4 x | -14.1 x |
| EV / FCF | -5.66 x | -3.98 x | -7.15 x | -7.86 x |
| FCF Yield | -17.7% | -25.1% | -14% | -12.7% |
| Price to Book | 2.25 x | 2.18 x | 3.92 x | 5.25 x |
| Nbr of stocks (in thousands) | 304,024 | 304,739 | - | - |
| Reference price 2 | 9.980 | 6.182 | 6.182 | 6.182 |
| Announcement Date | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 137.6 | 275.5 | 517.8 | 874 |
| EBITDA 1 | - | -498 | -443.7 | -329.3 | -163.5 |
| EBIT 1 | - | -538.9 | -476.2 | -372.3 | -208.1 |
| Operating Margin | - | -391.58% | -172.85% | -71.89% | -23.81% |
| Earnings before Tax (EBT) 1 | - | -1,964 | -472.9 | -377 | -200.3 |
| Net income 1 | -555.8 | -1,964 | -472.9 | -377 | -186.6 |
| Net margin | - | -1,426.91% | -171.64% | -72.8% | -21.35% |
| EPS 2 | -6.940 | -9.600 | -1.555 | -1.240 | -0.6137 |
| Free Cash Flow 1 | - | -437.2 | -529.7 | -295.1 | -293.9 |
| FCF margin | - | -317.7% | -192.26% | -56.98% | -33.63% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - |
| Announcement Date | 5/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 223 | 225 | 427 |
| Net Cash position 1 | - | 560 | - | - | - |
| Leverage (Debt/EBITDA) | - | - | -0.5023 x | -0.6832 x | -2.615 x |
| Free Cash Flow 1 | - | -437 | -530 | -295 | -294 |
| ROE (net income / shareholders' equity) | - | -3,823% | -45.7% | -60.4% | -42.1% |
| ROA (Net income/ Total Assets) | - | -125% | -29.8% | -24.5% | -15.4% |
| Assets 1 | - | 1,577 | 1,587 | 1,538 | 1,214 |
| Book Value Per Share 2 | - | 4.440 | 2.830 | 1.580 | 1.180 |
| Cash Flow per Share 2 | - | -1.860 | -1.670 | -0.9600 | -0.6700 |
| Capex 1 | - | 55.9 | 71.5 | 77.3 | 51.5 |
| Capex / Sales | - | 40.63% | 25.96% | 14.93% | 5.89% |
| Announcement Date | 5/30/23 | 3/27/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.182
CNY
Average target price
11.6
CNY
Spread / Average Target
+87.72%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -37.52% | 260M | |
| +60.25% | 841B | |
| +38.81% | 625B | |
| -4.49% | 360B | |
| +18.30% | 327B | |
| +9.64% | 300B | |
| +15.30% | 242B | |
| +3.44% | 228B | |
| +17.71% | 227B | |
| +12.87% | 174B |
- Stock Market
- Equities
- 2487 Stock
- Financials Cutia Therapeutics
